Pharmacyclics (PCYC) 10-Q 8 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 28, 2014
Document And Entity Information [Abstract]	'	'
Entity Registrant Name	'PHARMACYCLICS INC	'
Entity Central Index Key	'0000949699	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	75,032,044
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$678,625	$623,956
Marketable securities	11,431	11,672
Accounts receivable, net	27,013	11,044
Receivable from collaboration partners	1,047	51,957
Inventory	28,714	12,603
Advances to manufacturers	14,838	20,316
Prepaid expenses and other current assets	11,352	9,253
Total current assets	773,020	740,801
Property and equipment, net	29,800	25,471
Other assets	2,940	2,479
Total assets	805,760	768,751
Current liabilities:	'	'
Accounts payable	1,230	4,026
Accrued liabilities	63,161	71,188
Payable to collaboration partner	17,890	3,388
Income tax payable	30	1,448
Deferred revenue - current portion	12,862	7,581
Total current liabilities	95,173	87,631
Deferred revenue - non-current portion	44,648	52,025
Other long-term liabilities	1,568	1,472
Total liabilities	141,389	141,128
Commitments and contingencies (Notes 3 and 11)	'	'
Stockholders’ equity:	'	'
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2014 and December 31, 2013, respectively; shares issued and outstanding 75,025,090 and 74,167,169 at March 31, 2014 and December 31, 2013, respectively	8	7
Additional paid-in capital	862,693	844,220
Accumulated other comprehensive loss	-9	-8
Accumulated deficit	-198,321	-216,596
Total stockholders’ equity	664,371	627,623
Total liabilities and stockholders’ equity	$805,760	$768,751

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	75,025,090	74,167,169
Common stock, shares outstanding (in shares)	75,025,090	74,167,169

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Revenue:	'	'
License and milestone revenue	$60,000	$0
Product revenue, net	56,179	0
Collaboration services revenue	3,198	2,846
Total revenue	119,377	2,846
Costs and expenses:	'	'
Cost of goods sold	6,110	0
Research and development	35,292	35,784
Selling, general and administrative	34,715	20,026
Costs of collaboration (see Note 3)	25,035	0
Total costs and expenses	101,152	55,810
Income (loss) from operations	18,225	-52,964
Interest income	80	76
Other income (expense), net	-42	3
Income (loss) before income taxes	18,263	-52,885
Income tax benefit	-12	-974
Net income (loss)	$18,275	($51,911)
Net income (loss) per share:	'	'
Basic (in dollars per share)	$0.24	($0.73)
Diluted (in dollars per share)	$0.23	($0.73)
Weighted average shares used to compute net income (loss) per share:	'	'
Basic (in shares)	74,754	70,933
Diluted (in shares)	78,064	70,933

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Comprehensive income (loss), net of taxes	'	'
Net income (loss)	$18,275	($51,911)
Change in unrealized gain (loss) on marketable securities	-1	0
Comprehensive income (loss)	$18,274	($51,911)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Net income (loss)	$18,275	($51,911)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	911	392
Stock-based compensation expense	12,986	23,578
Loss on property and equipment	0	110
Changes in assets and liabilities:	'	'
Accounts receivable, net	-15,969	0
Receivable from collaboration partners	50,910	9,535
Inventory	-15,799	0
Advances to manufacturers	5,478	0
Prepaid expenses and other assets	-2,564	-2,725
Accounts payable	-2,806	9,881
Accrued liabilities	-7,046	8,252
Payable to collaboration partners	14,502	0
Income taxes payable	-1,418	-1,389
Deferred revenue	-2,096	-2,786
Other long-term liabilities	96	-1
Net cash provided by (used in) operating activities	55,460	-7,064
Cash flows from investing activities:	'	'
Purchase of property and equipment	-6,211	-2,087
Purchase of marketable securities	-2,640	-1,200
Proceeds from sales of marketable securities	0	240
Proceeds from maturities of marketable securities	2,880	1,920
Net cash used in investing activities	-5,971	-1,127
Cash flows from financing activities:	'	'
Issuance of common stock, net of issuance costs	0	201,023
Proceeds from exercise of stock options and stock purchase rights	5,180	2,261
Net cash provided by financing activities	5,180	203,284
Increase in cash and cash equivalents	54,669	195,093
Cash and cash equivalents at beginning of period	623,956	307,433
Cash and cash equivalents at end of period	678,625	502,526
Supplemental disclosure of non-cash investing and financing activities:	'	'
Receivable for stock option exercises	5	1
Property and equipment purchases included in Accounts payable and Accrued liabilities	$3,068	$2,373

The_Company_and_Significant_Ac

The Company and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
The Company and Significant Accounting Policies	'
	The Company and Significant Accounting Policies
	Company Overview
	Pharmacyclics, Inc. ("Pharmacyclics" or the "Company") is a biopharmaceutical company that designs, develops and commercializes therapies with a focus on product candidates that are small-molecule drugs for the treatment of cancer and immune-mediated diseases.
	On February 12, 2014, the U.S. Food and Drug Administration (FDA) approved IMBRUVICATM (ibrutinib, PCI-32765) under accelerated approval as a single agent for the treatment of patients with CLL who have received at least one prior therapy, the second indication for IMBRUVICATM. IMBRUVICATM first came to market on November 13, 2013, when the FDA approved IMBRUVICATM under accelerated approval as a single agent for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The FDA approval for these indications was based on overall response rate (ORR). Improvements in survival or disease-related symptoms has not been established. IMBRUVICATM is the first once-daily, single-agent, oral kinase inhibitor for patients with MCL and patients with CLL who in each case have received one prior therapy and is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc. and its affiliates ("Janssen"), one of the Janssen Pharmaceutical companies of Johnson & Johnson.
	In addition to IMBRUVICATM (ibrutinib), Pharmacyclics has three other product candidates in clinical development and several preclinical molecules in lead optimization.
	Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of Pharmacyclics, Inc. and its wholly-owned subsidiaries, Pharmacyclics (Europe) Limited, Pharmacyclics Switzerland GmbH, Pharmacyclics Cayman Ltd. and Pharmacyclics (Shanghai) Management Consulting Service Limited. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's consolidated operations.
	The interim condensed consolidated financial statements have been prepared by the Company, without audit, in accordance with Article 10 of Regulation S-X which governs quarterly reporting and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of the Company's financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States ("GAAP"). The December 31, 2013 condensed consolidated balance sheet data contained within this Form 10-Q was derived from audited consolidated financial statements included in the Company's Form 10-K for the year ended December 31, 2013, but does not include all disclosures required by accounting principles generally accepted in the United States.
	In the opinion of management, the unaudited financial information for the interim periods presented reflects all normal and recurring adjustments necessary for a fair statement of results of operations, financial position and cash flows. These condensed consolidated financial statements should be read in conjunction with the financial statements included in the Company's Form 10-K for the year ended December 31, 2013. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year.
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and the disclosure of contingent amounts in the Company's condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.
	Reclassification
	Certain amounts within the condensed consolidated balance sheet for the prior periods have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company's previously reported financial position.
	Significant Accounting Policies
	In connection with the Company's commercial launch of IMBRUVICATM on November 13, 2013, it implemented the following significant accounting policies and estimates that are used in the determination of product revenue, net:
	Revenue recognition
	Product revenue, net is recognized in accordance with the FASB Accounting Standards Codification (ASC) 605, Revenue Recognition, when the following criteria have been met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. The Company exercises judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. The Company assesses collectability based primarily on the customer's payment history and on the creditworthiness of the customer.
	Product Revenue, Net
	Product revenue, net consists of U.S. sales of IMBRUVICATM and is recognized once all four revenue recognition criteria described above have been met. The Company sells IMBRUVICATM to specialty pharmacies ("SP") that sells to individual patients, specialty distributors ("SD") that sells to hospital pharmacies, and to direct customers. The Company recognizes revenue from sales of IMBRUVICATM when the product’s title and risk of loss transfers to the customer. The Company determined that it has the ability to make reasonable estimates of product returns in order to recognize revenue at the time that title and risk of loss transfers to the customer based on the following factors: (1) the Company believes that it has sufficient insight into the distribution channel at the SP's and SD's in order to ascertain their inventory level and dispense data, (2) due to the price of the Company's product and limited patient population, its SP and SD customers have not built up significant levels of inventory, nor does the Company expect they will do so for the foreseeable future, (3) inventory on hand at the Company's SP customers was generally less than two weeks as of March 31, 2014, (4) there have been no product returns to-date since the Company's commercial launch of IMBRUVICATM on November 13, 2013 and (5) the Company believes there is limited risk of return of inventory in the channel due to expiration based on the shelf life of inventory in the channel.
	The Company recognizes product revenue net of adjustments for customer credits, including estimated government rebates and charge-backs, returns, prompt payment discounts, patient assistance programs, and Medicare Part D coverage gap reimbursements. Each of the above adjustments are recorded at the time of revenue recognition, resulting in a reduction in product revenue, net and an increase in accrued expenses or a reduction in accounts receivable, net. The above adjustments require significant estimates, judgment and information obtained from external sources. If management's estimates differ from actuals, the Company will record adjustments that would affect product revenue, net in the period of adjustment.
	Gross-to-net sales adjustments
	Rebates
	The Company records an allowance for rebates including mandated discounts under the Medicaid Drug Rebate Program. The allowance for rebates is based upon contractual agreements or legal requirements with public sector benefit providers, including Medicaid. The allowance for rebates represents the estimated amounts owed to such public sector benefit providers, including Medicaid, based on the estimated rebate percentage of forecasted eligible Medicaid sales. The estimated rebate percentage is based on statutory discount rates and expected utilization. The forecasted eligible Medicaid sales represents those sales made by the Company that will ultimately be consumed by patients covered by Medicaid. To estimate the allowance for rebates, the Company uses the estimated patient mix information which is provided by our specialty pharmacy customers, as well as third party sources. Rebates are generally invoiced and paid in arrears. As such, the allowance for rebates consists of an estimate of the amount expected to be incurred for the current quarter's shipments to patients, plus an accrual balance for estimated unpaid rebates from prior periods. The allowance for rebates is recorded within Accrued liabilities in the condensed consolidated balance sheets.
	Charge-backs
	Charge-backs are discounts that result from the difference between the prices at which the Company sells IMBRUVICATM to direct customers and the sales price ultimately paid to wholesalers under fixed price contracts by third-party payers. Such third-party payers, which primarily consist of the U.S. Department of Defense, U.S. Department of Veteran's Affairs (VA), Public Health Services (PHS), and other Federal Government institutions purchasing via the Federal Supply Schedule, purchase products through wholesalers at a lower price provided for in fixed price contracts and the wholesalers then charge the Company the difference between their acquisition cost and the lower program price. Charge-backs are recorded as a reduction to accounts receivable, net in the condensed consolidated balance sheets.
	Product Returns
	Consistent with industry practice, the Company generally offers its customers a limited right to return. The Company generally allows for the return of product that is a few months prior to and up to a few months after the product expiration date. Additionally, the Company considers several other factors in the estimation process including the expiration dates of product shipped, third party data in monitoring channel inventory levels, shelf life of the product, prescription trends and other relevant factors. Provisions for estimated product returns are recorded within Accrued liabilities in the condensed consolidated balance sheets.
	Medicare Part D coverage gap
	Medicare Part D, also known as the Medicare prescription drug benefit, is a federal program to subsidize the costs of prescription drugs for Medicare beneficiaries in the United States. The Medicare Part D prescription drug benefit mandates that drug manufacturers fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Funding of the Medicare Part D gap is invoiced and paid in arrears. As such, the allowance for Medicare Part D consists of an estimate of the amount expected to be incurred for the current quarter's shipments to patients, plus an accrual balance for estimated shipments remaining in the channel at period end which are estimated to ship to Medicare Part D patients. The allowance for rebates is recorded within Accrued liabilities in the condensed consolidated balance sheets.
	Prompt payment discounts
	The Company generally offers cash discounts to its customers, generally a 2% discount applied to the invoice amount, as an incentive for prompt payment. The Company expects that all of its customers to whom it offers cash discounts for prompt payment to take advantage of the full amount of the 2% discount. The Company records the prompt-payment discount as a reduction to Accounts receivable, net in the condensed consolidated balance sheets.
	Co-payment assistance
	Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.
	Donations to Third-Party Patient Assistance Foundations
	The Company provides cash donations to independent third-party patient assistance foundations that, in turn, make grants to help qualifying patients meet their out-of-pocket costs (including co-pay payments or co-insurance obligations) in connection with their use of the Company's products as well as those of other pharmaceutical and biotechnology companies. These independent patient assistance foundations maintain their own patient eligibility criteria and independently determine for which medicinal products patients can receive financial assistance. Given the non-reciprocal nature of these transactions with parties who are not considered direct or indirect customers, and for which the Company does not receive any consideration, and the fact that the donation of cash does not have any conditions attached to the donation, the Company accounts for the cash donations as a component of selling, general and administrative expenses in the condensed consolidated statements of operations.
	For a complete listing of the Company's significant accounting policies, please see Note 2 to its consolidated financial statements included in its Form 10-K for the year ended December 31, 2013.
	Concentration of credit risk
	Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, marketable securities, accounts receivable and receivables from collaboration partners. The Company places its cash and cash equivalents with high-credit quality financial institutions and invests in debt instruments of financial institutions, corporations and government entities with strong credit ratings. The Company's management believes it has established guidelines relative to credit quality, diversification and maturities that maintain safety and liquidity.
	The Company sells IMBRUVICATM to direct customers and through a limited number of specialty pharmacies and specialty distributors. The Company continuously monitors the creditworthiness of its customers and has internal policies regarding customer credit limits. The Company's policy is to estimate the allowance for doubtful accounts based on the credit worthiness of its customers, historical payment patterns, the aging of accounts receivable balances and general economic conditions. As of March 31, 2014, the Company had no allowance for doubtful accounts. For the three months ended March 31, 2014, 5 individual customers accounted for 30%, 16% , 15%, 11%, and 10% of accounts receivable, net, respectively.

Product_Revenue_Net

Product Revenue, Net	3 Months Ended
	Mar. 31, 2014
Revenues [Abstract]	'
Product Revenue, Net	'
	Product Revenue, Net
	Product revenue, net consists of revenue recorded on the sale of IMBRUVICATM which was approved by the FDA and commercially launched by the Company on November 13, 2013 for MCL. On February 12, 2014, the FDA approved and the Company launched IMBRUVICATM for CLL. All product sales during three months ended March 31, 2014 were shipped to specialty pharmacies, specialty distributors and direct customers in the United States.
	The following table summarizes the provisions, and credits/payments, for product revenue, net adjustments (in thousands):
			Total
	Balance as of December 31, 2013		$	1,206
	Provision related to current period sales		8,639
	Credits/payments		(2,095		)
	Balance as of March 31, 2014		$	7,750
	The following table sets forth customers who represented 10% or more of the Company's product revenue, net for the three months ended March 31, 2014:
		Three Months Ended
	Customer	31-Mar-14
	A	29	%
	B	19	%
	C	13	%
	D	12	%

Collaboration_and_Other_Agreem

Collaboration and Other Agreements	3 Months Ended
	Mar. 31, 2014
Collaboration and Other Agreements [Abstract]	'
Collaboration and Other Agreements	'
	Collaboration and Other Agreements
	The Company recognized revenue related to its collaboration and license arrangements as follows (in thousands):
		Three Months Ended March 31,
		2014			2013
	Janssen	$	63,135		$	2,786
	Les Laboratoires Servier ("Servier")	63			40
	Other	—			20
	Total	$	63,198		$	2,846
	Collaboration and License Agreement with Janssen Biotech, Inc.
	Background
	In December 2011, the Company entered into a worldwide collaboration and license agreement (the "Agreement") with Janssen for the development and commercialization of IMBRUVICATM, a novel, orally active, selective covalent inhibitor of Bruton’s Tyrosine Kinase ("BTK"), and certain compounds structurally related to IMBRUVICATM, for oncology and other indications, excluding all immune and inflammatory mediated diseases or conditions and all psychiatric or psychological diseases or conditions, in the U.S. and outside the U.S.
	The collaboration provides Janssen with an exclusive license to exploit the underlying technology outside of the U.S. (the “License Territory”) and co-exclusively with Pharmacyclics in the U.S.
	The collaboration has no fixed duration or expiration date and provided for payments by Janssen to the Company of a $150,000,000 non-refundable upfront payment upon execution, as well as potential future milestone payments of up to $825,000,000, based upon continued development progress ($250,000,000), regulatory progress ($225,000,000) and approval of the product in both the U.S. and the License Territory ($350,000,000). As of March 31, 2014, $445,000,000 in milestone payments have been earned by the Company under the Agreement and it may receive up to an additional $380,000,000 in development, regulatory and approval milestone payments. However, clinical development entails risks and we have no assurance as to whether or when the milestone targets might be achieved.
	The development, regulatory and approval milestones represents non-refundable amounts that would be paid by Janssen to the Company if certain milestones are achieved in the future. The Company has elected to apply the guidance in ASC 605-28 to the milestones. These milestones, if achieved, are substantive as they relate solely to past performance, are commensurate with estimated enhancement of value associated with the achievement of each milestone as a result of the Company's performance, which are reasonable relative to the other deliverables and terms of the arrangement, and are unrelated to the delivery of any further elements under the arrangement.
	The Agreement includes a cost sharing arrangement for associated collaboration activities. Except in certain cases, in general Janssen is responsible for approximately 60% of collaboration development costs and the Company is responsible for the remaining 40% of collaboration development costs. In general, costs associated with commercialization will be included in determining pre-tax profit or pre-tax loss, which are to be shared 50% by the Company and 50% by Janssen.
	The collaboration with Janssen provides the Company with an annual cap of its share of IMBRUVICATM related research and development expenses and selling, general and administrative expenses offset by pre-tax commercial profits for each calendar year. In the event that the Company's share of aggregate development costs in any given calendar year, together with any other amounts that become due from the Company, plus the Company's share of pre-tax loss (if any) for any calendar quarter in such calendar year, less the Company's share of pre-tax profit (if any) for any calendar quarter in such calendar year, exceeds $50,000,000, then amounts that are in excess of $50,000,000 (the "Excess Amounts") are funded by Janssen. Under the Agreement, total Excess Amounts plus interest may not exceed $225,000,000.
	The total Excess Amounts plus interest may not exceed $225,000,000 at any given time.  Interest shall be accrued on the outstanding balance with interest calculated at the average annual European Interbank Offered Rate ("EURIBOR") for the EURO or average annual London Interbank Offered Rate ("LIBOR") for U.S. Dollars as reported in the Wall Street Journal, plus 2%, calculated on the number of days from the date on which the Company's payment would be due to Janssen. The interest rate on outstanding Excess Amounts shall not exceed 5% per annum, and the cumulative interest on Excess Amounts shall not in the aggregate exceed $25,000,000.
	In the event the Excess Amounts plus interest reaches a maximum of $225,000,000, the Company shall be responsible for its share of development costs, together with any other amounts that become due from the Company, plus its share of any pre-tax loss beyond such maximum. For all calendar quarters following the Company's third profitable calendar quarter, as determined in the Agreement, the Company can no longer add to Excess Amounts and shall be responsible for its own share of development costs along with its share of pre-tax losses incurred in such quarters. Janssen may only recoup the Excess Amounts, together with interest from the Company's share of pre-tax profits (if any) in calendar quarters subsequent to its third profitable calendar quarter until the Excess Amounts and applicable interest has been fully repaid.
	The Company recognizes Excess Amounts as a reduction to costs and expenses as the Company's repayment of Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product. Further, Excess Amounts shall be reimbursable only as a reduction of the Company's share of pre-tax profits (if any) after the third profitable quarter for the product.
	The Agreement also provides that any net profits from the commercialization of products resulting from the collaboration will be shared 50% by the Company and 50% by Janssen. Both parties are responsible for the development, manufacturing and marketing of any products resulting from the Agreement. Janssen has sole responsibility and exclusive rights to commercialize the products in the License Territory. The parties hold joint responsibility and co-exclusive rights to commercialize the products in the U.S., and Pharmacyclics will serve as the lead party in such effort. The Company continues to work with Janssen on protocols and the design, schedules and timing of trials.
	In accordance with ASU No. 2009-13 (and as incorporated into ASC Topic 605-25), the Company identified all of the deliverables at the inception of the Agreement. The significant deliverables were determined to be the license, committee services, development services and commercialization services. The commercialization services represent a contingent deliverable for which there is not a significant incremental discount.
	The Company has determined that the license represents a separate unit of accounting as the license, which includes rights to the underlying technologies for IMBRUVICATM, has standalone value apart from the committee and development services because the development, manufacturing and commercialization rights conveyed would permit Janssen to perform all efforts necessary to bring the compound to commercialization and begin selling the drug upon regulatory approval. The Company has also determined that the committee and development services each represent individual units of accounting as they have standalone value from each other.  The Company has determined its best estimate of selling prices for the license unit of accounting based on the income approach as defined in ASC 820-10-35-32. This measurement is based on the value indicated by current estimates about those future amounts and reflects management determined estimates and assumptions. These estimates and assumptions include, but are not limited to, how a market participant would use the license, estimated market opportunity and expected market share and assumed royalty rates that would be paid for sales resulting from products developed using the license, similar arrangements entered into by third parties and entity-specific factors such as the terms of the Company's previous collaborative agreement, the Company's pricing practices and pricing objectives, the likelihood that clinical trials will be successful, the likelihood that regulatory approval will be received and that the products will become commercialized and the markets served. These estimates and assumptions led to an expected future cash flow which was discounted based on estimated weighted average cost of capital of 12% and royalty rates ranging from 30% to 40%. The Company has also determined its best estimate of selling prices for the committee and development services, based on the nature of the services to be performed and estimates of the associated effort as well as estimated market rates for similar services. The arrangement consideration of $150,000,000 was allocated to the units of accounting based on the relative selling price method.
	Of the $150,000,000 upfront payment received, $70,605,000 was allocated to the licenses, $14,982,000 to the committee services and $64,413,000 to the development services. The Company has recognized license revenue upon execution of the arrangement as the associated unit of accounting had been delivered pursuant to the terms of the Agreement. At inception, the $14,982,000 and $64,413,000 allocated to committee and development services, respectively, is being recognized as revenue as the related services are provided over the estimated service periods of 17 years and 9 years, which are equivalent to the estimated remaining life of the underlying technology and the estimated remaining development period, respectively.
	Janssen Collaboration Revenue
	Total revenue recognized with respect to the Agreement consisted of the following (in thousands):
		Three Months Ended March 31,
		2014			2013
	License and milestone revenue	$	60,000		$	—
	Collaboration services revenue	3,135			2,786
	Total	$	63,135		$	2,786
	For the three months ended March 31, 2014, the Company recognized $60,000,000 of milestone revenue under its collaboration agreement with Janssen. As previously announced, the $60,000,000 milestone payment to the Company was triggered on February 12, 2014 as a result of the FDA approval of IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia (“CLL”) who have received at least one prior therapy.
	As of March 31, 2014, total deferred revenue related to committee and development services under the Agreement with Janssen was $56,946,000, of which $44,648,000 was included in deferred revenue non-current portion.
	Janssen Collaboration Cost Sharing and Excess Amounts
	The Company recognized development costs under the collaboration as a component of research and development expense in the condensed consolidated statements of operations. The Company also recognized certain selling, general and administrative expenses under the collaboration, including marketing costs, patent costs and the Company's share of pre-tax commercial losses on sales of IMBRUVICATM as a component of selling, general and administrative in the condensed consolidated statements of operations. Expenses which were charged to the collaboration are as follows (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Collaboration expenses, unadjusted	$	32,365		$	38,463
	Decrease for cost sharing	(7,963		)	(16,291		)
	Research and development	$	24,402		$	22,172
	Collaboration expenses, unadjusted	$	18,220		$	3,508
	Decrease for cost sharing	(55		)	(811		)
	Selling, general and administrative	$	18,165		$	2,697
	During the three months ended March 31, 2014 and the three months ended March 31, 2013, the Company's share of costs under the Agreement was calculated as follows:
		Three Months Ended
		March 31,
		2014			2013
	Research and development	$	24,402		$	22,172
	Selling, general and administrative	18,165			2,697
		42,567			24,869
	Less: Pharmacyclics' 50% share of net product revenue less cost of goods sold	25,035			—
	Total net costs for IMBRUVICATM under the Agreement (1)	$	17,532		$	24,869
	(1) The Company's total share of net costs under the Agreement did not exceed the $50,000,000 annual cap provided for in the Agreement. As such, no Excess Amounts were recorded for the three months ended March 31, 2014 and March 31, 2013.
	For the three months ended March 31, 2014, Janssen's 50% share from net product revenue less cost of goods sold of IMBRUVICATM of $25,035,000 was included in Costs of collaboration in the Company's condensed consolidated statements of operations. Janssen's share was calculated as follows:
		Three Months Ended
		31-Mar-14
	Product revenue, net	$	56,179
	Less: Cost of goods sold	6,110
		50,069
	Janssen's share of pre-tax profits	50		%
	Total Cost of Collaboration (Janssen's 50% share as per the Agreement)	$	25,035
	Pharmacyclics' 50% share of net product revenue less cost of goods sold	$	25,035
	As of March 31, 2014, the Company had $1,047,000 receivable from Janssen which primarily was related to materials and product purchases. As of December 31, 2013, the Company had $50,230,000 receivable from Janssen related to Excess Amounts and $1,607,000 due from Janssen related to value added taxes. The receivable from Janssen is included within receivable from collaboration partners on the condensed consolidated balance sheets.
As of March 31, 2014, the Company had $17,890,000 payable to Janssen which primarily consisted of amounts due for Janssen's share of pre-tax profits. As of December 31, 2013, the Company had $3,142,000 payable to Janssen under the cost sharing arrangement and $246,000 due to Janssen related to value added taxes. The payable to Janssen is included within payable to collaboration partner on the condensed consolidated balance sheets.
As of March 31, 2014, total Excess Amounts of $135,634,000 (which comprises the cumulative amount funded by Janssen to-date of $134,261,000 and interest of $1,373,000) would become payable once the Company reaches a third profitable calendar quarter for the product. Further, Excess Amounts shall be reimbursable only from the Company's share of pre-tax profits (if any) after the third profitable calendar quarter for the product.
Collaboration and License Agreement with Servier
In April 2009, the Company entered into a collaboration and license agreement with Servier to research, develop and commercialize abexinostat (PCI-24781), an orally active, novel, small molecule inhibitor of pan-HDAC enzymes. Under the terms of the agreement, Servier acquired the exclusive right to develop and commercialize the pan-HDAC inhibitor product worldwide except for the United States and will pay development and regulatory milestones and a royalty to the Company on sales outside of the United States. Servier is solely responsible for conducting and paying for all development activities outside the United States. The Company continues to own all rights within the United States.
In May 2009, the Company received an upfront payment from Servier of $11,000,000 ($10,450,000 net of withholding taxes) and the Company received an additional $4,000,000 for research collaboration paid over a twenty-four months period through April 2011. The revenue related to these payments was recognized over the two-years period, which ended in April 2011.
Under this agreement with Servier, the Company is also eligible to receive up to $24,500,000 in milestone payments upon achievement of pre-specified events; including up to $10,500,000 for the achievement of development milestones ($7,000,000 of which was paid to the Company, in advance, during April 2011), up to $5,000,000 for the achievement of regulatory progress and up to $9,000,000 for regulatory approval of the pan HDAC product in major jurisdictions. In addition, Servier agreed to make royalty payments on net sales of the licensed product as defined in the agreement. In October 2011, the milestone related to the $7,000,000 advance payment was achieved and the Company recognized the amount as revenue.
Total revenue recognized with respect to the Company's collaboration and license agreement with Servier consisted of the following (in thousands):
	Three Months Ended
	March 31,
	2014			2013
Collaboration services revenue	$	63		$	40
Total	$	63		$	40
License agreement with Novo Nordisk A/S
In October 2012, the Company entered into a license agreement with Novo Nordisk A/S ("Novo Nordisk"). Under the terms of the agreement, Novo Nordisk acquired the exclusive worldwide rights for the Company's small molecule Factor VIIa inhibitor, PCI-27483 as an excipient in a product containing a Novo Nordisk active pharmaceutical ingredient for a restricted disease indication outside of oncology. Novo Nordisk will utilize PCI-27483 as an excipient in a product within Novo Nordisk's biopharmaceutical unit. Novo Nordisk is solely responsible for all further research and development activities within the restricted disease indication outside of oncology.
In connection with entering into the license agreement with Novo Nordisk, the Company received an upfront payment of $5,000,000 in October 2012. In addition, the Company may receive up to $55,000,000 based on the achievement of certain development, regulatory and sales milestones. Upon commercialization, the Company will also receive low single digit tiered royalties on Novo Nordisk's net sales of biopharmaceutical formulations utilizing the addition of PCI-27483.
On June 28, 2013, the Company entered into an amended and restated license agreement with Novo Nordisk to expand the scope of the license granted by the Company to Novo Nordisk in October 2012. Under the amended and restated license agreement with Novo Nordisk, the Company has no additional obligations related to the delivery of the license.
Celera Corporation
In April 2006, the Company acquired multiple small molecule drug candidates for the treatment of cancer and other diseases from Celera Genomics, an Applera Corporation business  (now Celera Corporation - a subsidiary of Quest Diagnostics Incorporated). Future milestone payments under the agreement, as amended, could total as much as approximately $97,000,000, although the Company currently cannot predict if or when any of the milestones will be achieved. Approximately two-thirds of the milestone payments relate to the Company's HDAC inhibitor program and approximately one-third relates to the Company's Factor VIIa inhibitor program. Approximately 90% of the potential future milestone payments would be paid to Celera after obtaining regulatory approval in various countries. To date, no milestone payments have been triggered related to the Company's HDAC inhibitor or Factor VIIa programs.
In addition to the milestone payments, the Company is required to make single-digit royalty payments based on annual sales of IMBRUVICATM and would be required to make single-digit royalty payments based on annual sales of drugs commercialized from the Company's HDAC inhibitor, Factor VIIa inhibitor and certain other BTK inhibitor programs. For the three months ended March 31, 2014, the Company recognized royalty expense under the Celera agreement of approximately $3,931,000 on net product sales of IMBRUVICATM in the United States. Royalty expense related to net product sales of IMBRUVICATM is included within cost of goods sold in the condensed consolidated statement of operations. No royalty expense was recognized under the Celera agreement for the three months ended March 31, 2013.
For any BTK inhibitor product or Factor VIIa inhibitor product obtained from Celera, the agreement with Celera expires on a product-by-product and country-by-country basis. The term of the agreement for a given BTK inhibitor product shall expire in a given country upon the expiration of the last-to-expire Celera patent assigned to the Company that covers the manufacture, use, sale, offer for sale, or importation of such product in such country. For any HDAC inhibitor product obtained from Celera, the agreement with Celera expires on a product-by-product and country-by-country basis. The term of the agreement for a given HDAC inhibitor product shall expire in a given country upon the expiration of the last-to-expire Celera patent assigned to the Company that covers the sale of such product in such country.
The Company may terminate the agreement with Celera in its entirety, or with respect to one or more of the three classes of products (BTK inhibitor products, HDAC inhibitor products and Factor VIIa inhibitor products) obtained from Celera, at any time by giving Celera at least 60 days' prior written notice. If the Company terminates the agreement with respect to a particular class of products, ownership of the Celera intellectual property assigned to the Company relating to the products in the terminated product class will revert to Celera. If the Company terminates the agreement in its entirety, ownership of all of the Celera intellectual property assigned to the Company will revert to Celera.
The agreement with Celera may be terminated effective immediately upon a party's written notice to the other party for a breach by the other party that remains uncured for 90 days after notice of the breach is given to the breaching party. If the Company breaches the agreement only with respect to one or two of the three classes of products obtained from Celera, but not with respect to all three classes of products, and if the Company's breach remains uncured for 90 days after the Company has received notice of breach from Celera, Celera may terminate the agreement solely with respect to the class or classes of products affected by the Company's breach, but may not terminate the agreement with respect to the class or classes of products unaffected by the Company's breach.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventory
	Inventories consist of raw materials, work-in-process and finished goods related to the production of IMBRUVICATM. Raw materials include IMBRUVICATM active pharmaceutical ingredient (API). Work-in-process includes third-party manufacturing and associated labor costs relating to the Company’s personnel involved in the production process. Included in inventories are raw materials and work-in-process that may be used as clinical products, which are charged to research and development expense when the product enters the research and development process.
	The components of inventory are as follows (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	14,899	$	8,007
	Work-in-process	11,651		3,489
	Finished goods	2,164		1,107
		$	28,714	$	12,603
	The Company records cash advances that it pays prior to the receipt of inventory as advances to manufacturers in the condensed consolidated balance sheets. The cash advances may be forfeited if the Company terminates the scheduled production. The Company expects the carrying value of the advances to manufacturers to be fully realized.

Fair_Value_Measurements_and_Ma

Fair Value Measurements and Marketable Securities	3 Months Ended
	Mar. 31, 2014
Assets, Fair Value Disclosure [Abstract]	'
Fair Value Measurements and Marketable Securities	'
	Fair Value Measurements and Marketable Securities
	The Company's marketable securities are classified as “available-for-sale.” The Company includes these investments in current assets and carries them at fair value. Unrealized gains and losses on available-for-sale securities are included in accumulated other comprehensive loss. The amortized cost of debt securities is adjusted for the amortization of premiums and accretion of discounts to maturity. Such amortization is included in interest income in the condensed consolidated statements of operations. Gains and losses on securities sold are recorded based on the specific identification method and are included in other income (expense), net in the condensed consolidated statements of operations.
	Management assesses whether declines in the fair value of marketable securities are other than temporary. If the decline is judged to be other than temporary, the cost basis of the individual security is written down to fair value and the amount of the write down is included in the statement of operations. In determining whether a decline is other than temporary, management considers various factors including the length of time and the extent to which the market value has been less than cost, the financial condition and near-term prospects of the issuer and the Company's intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.
	The fair value of the Company's financial assets and liabilities is determined by using three levels of input which are defined as follows:
	Level 1 - Quoted prices in active markets for identical assets or liabilities. At March 31, 2014, the Company's Level 1 assets were comprised of U.S. treasury securities and money market funds.
	Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company's short-term investments primarily utilize broker quotes in markets with infrequent transactions for valuation of these securities. At March 31, 2014, the Company's Level 2 assets were comprised of U.S. agency securities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. At March 31, 2014, the Company did not hold any Level 3 assets.
	The Company utilizes the market approach to measure fair value for its financial assets and liabilities. The market approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
	The following is a summary of the Company's available-for-sale securities at March 31, 2014 and December 31, 2013, respectively (in thousands):
	As of March 31, 2014		Amortized Cost			Unrealized Gain			Unrealized Loss				Estimated Fair Value
	U.S. agency securities – FDIC insured		$	11,440		$	—		$	(9	)		$	11,431
	Total marketable securities		$	11,440		$	—		$	(9	)		$	11,431
	As of December 31, 2013		Amortized Cost			Unrealized Gain			Unrealized Loss				Estimated Fair Value
	U.S. agency securities – FDIC insured		$	11,680		$	—		$	(8	)		$	11,672
	Total marketable securities		$	11,680		$	—		$	(8	)		$	11,672
	At March 31, 2014, the Company's marketable securities had the following remaining contractual maturities (in thousands):
		Amortized Cost			Estimated Fair Value
	Less than one year	$	11,440		$	11,431
	The following table sets forth the basis of fair value measurements for the Company's cash equivalents and available-for-sale securities as of March 31, 2014 and December 31, 2013 (in thousands):
		March 31, 2014
		Level 1			Level 2			Level 3				Fair value
	Cash equivalents:
	U.S. treasury bills	$	474,985		$	—		$	—			$	474,985
	Money market funds	79,304			—			—				79,304
	U.S. agency securities - FDIC insured	—			240			—				240
	Marketable securities:
	U.S. agency securities - FDIC insured	—			11,431			—				11,431
		$	554,289		$	11,671		$	—			$	565,960
		31-Dec-13
		Level 1			Level 2			Level 3				Fair value
	Cash equivalents:
	U.S. treasury bills	$	269,488		$	—		$	—			$	269,488
	Money market funds	129,193			—			—				129,193
	U.S. agency securities - FDIC insured	—			240			—				240
	Marketable securities:
	U.S. agency securities - FDIC insured	—			11,672			—				11,672
		$	398,681		$	11,912		$	—			$	410,593

Balance_Sheet_Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2014
Balance Sheet Related Disclosures [Abstract]	'
Balance Sheet Components	'
	Balance Sheet Components
	Property and equipment, net, consists of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Equipment	$	12,559		$	11,827
	Leasehold improvements	5,528			5,493
	Furniture and fixtures	1,278			1,278
	Construction in progress	19,065			14,592
		38,430			33,190
	Less: Accumulated depreciation and amortization	(8,630		)	(7,719		)
		$	29,800		$	25,471
	Accrued liabilities consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Accrued clinical related	$	17,166		$	17,062
	Accrued payroll and employee related expenses	16,006			20,500
	Accrued inventory	1,528			7,592
	Gross to net accruals	5,995			905
	Accrued contract manufacturing	1,256			1,556
	Accrued royalty	4,167			949
	Accrued outside services	3,583			5,077
	Accrued property and equipment purchases	3,028			4,039
	Accrued value added taxes	1,654			7,041
	Accrued other	8,778			6,467
		$	63,161		$	71,188
	Deferred revenue consists of the following (in thousands):
	Current portion:	March 31,			December 31,
		2014			2013
	Deferred revenue related to Janssen	$	12,297		$	7,505
	Deferred revenue related to net product sales	565			76
		$	12,862		$	7,581
	Non-current portion:	March 31,			December 31,
		2014			2013
	Deferred revenue from Janssen	$	44,648		$	52,025

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The income tax provision includes U.S. federal, state and local, and foreign income taxes and is based on the application of a forecasted annual income tax rate applied to the year-to-date pre-tax income (loss). In determining the estimated annual effective income tax rate, the Company analyzes various factors including projections of its annual earnings, the tax jurisdictions in which the earnings will be generated, the impact of state and local income taxes, its ability to use tax credits and net operating loss carryforwards and available tax planning alternatives. Discrete items including the effect of changes in tax laws, tax rates and certain circumstances with respect to valuation allowances or other unusual or non-recurring tax adjustments are reflected in the period in which they occur.
	For the three months ended March 31, 2014, the Company recorded an income tax benefit of $12,000 compared to an income tax benefit of $974,000 for the three months ended March 31, 2013. The difference between the estimated annual effective tax rate and the federal statutory rate of 35% was primarily attributable to discrete benefits recorded in the period. For the three months ended March 31, 2014, no tax benefit has been recorded under an effective tax rate method as no benefit is expected to be realized for the current year given the Company's full valuation allowance position and also based on the Company's estimate of a tax provision for the year ending December 31, 2014. For the three months ended March 31, 2013, the income tax benefit was primarily related to the reversal of previously recorded Federal Alternative Minimum Tax partially offset by foreign tax expense.
	The Company recorded a valuation allowance against all of its net deferred tax assets at both March 31, 2014 and December 31, 2013. The Company intends to continue maintaining a full valuation allowance on its deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances. However, considering the Company's current assessment of the probability of earning future milestones under its collaboration agreements and income from potential future sales of IMBRUVICATM, there is a reasonable possibility that, within the next year, sufficient positive evidence may become available to reach a conclusion that a significant portion of the valuation allowance will no longer be needed. As such, the Company may release a significant portion of its valuation allowance against its deferred tax assets within the next 12 months. This release would result in the recognition of certain deferred tax assets and a decrease to income tax expense for the period such release is recorded.
	The total amount of the unrecognized tax benefits if recognized would be an adjustment to the amount of deferred tax assets reported. The Company may from time to time be assessed interest or penalties by major tax jurisdictions, although there have been no such assessments historically. In the event the Company receives an assessment for interest and/or penalties, it would be classified in the financial statements as income tax expense. As of March 31, 2014, all tax years in the U.S. remain open due to the taxing authorities' ability to adjust operating loss carry forwards. The Company does not expect any material changes to the unrecognized tax benefits reported above during the next twelve months. The Company is unable to make a reasonable estimate as to when cash settlements with the relevant taxing authorities will occur.
	During the year ended December 31, 2013, the Company was notified by the Internal Revenue Service (IRS) that it will be audited for the tax years ended June 30, 2012 and 2011. As of March 31, 2014, no adjustments have been proposed by the IRS.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Facilities Lease
	As of March 31, 2014, the Company leases 132,176 square feet for its corporate headquarters in Sunnyvale, California. Of this total space, 79,776 square feet are leased under an operating lease that expires in November 2017, with an option to extend the lease term for an additional five years. The remaining 52,400 square feet, of which 32,000 square feet represents additional space that the Company exercised an option to lease during the year ended December 31, 2013, is leased under an operating lease which expires in February 2023 and has an option to extend the lease term for an additional five years. In addition, during the year ended December 31, 2013, the Company entered into an agreement to lease approximately 7,500 square feet for its Pharmacyclics Switzerland GmbH office under an agreement that expires in May 2015. During the year ended December 31, 2013, the Company entered into an agreement to lease 7,000 square feet of office space in South San Francisco, California under an operating lease which expires in September 2014.
	The Company recognizes rental expense on the facilities on a straight-line basis over the lease term. Differences between the straight line rent expense and rent payments are classified as deferred rent liability on the balance sheet. As of March 31, 2014, the Company's future minimum lease payments under non-cancelable operating leases are as follows:
	Fiscal year	Operating Lease Commitments
	2014 (remaining nine months)	$	1,677
	2015	2,092
	2016	2,161
	2017	2,112
	2018	857
	2019	882
	Thereafter	2,890
	Total	$	12,671
	Purchase Commitments
	The Company had non-cancelable purchase obligations for approximately $12,840,000 and $34,800,000 as of March 31, 2014 and December 31, 2013, respectively.
	Excess Amounts under collaboration and license agreement with Janssen
	The Company's worldwide collaboration and license agreement with Janssen provides the Company with an annual cap of its share of development costs and pre-tax losses for each calendar year until the third profitable calendar quarter for the product, as determined in the agreement and any Excess Amounts are funded by Janssen. As of March 31, 2014, total Excess Amounts of $135,634,000 (which is comprised of the cumulative amount funded by Janssen to-date of $134,261,000 and interest of $1,373,000) would become payable once the Company reaches a third profitable calendar quarter for the product (see Note 3). Janssen may recoup the Excess Amounts, together with interest from the Company's share of pre-tax profits (if any) in calendar quarters subsequent to its third profitable quarter for the product until the Excess Amounts and applicable interest has been fully repaid.
	Legal Proceedings
	The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s condensed consolidated financial position, results of operations or cash flows.

Basic_and_Diluted_Net_Income_P

Basic and Diluted Net Income Per Share	3 Months Ended
	Mar. 31, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Basic and Diluted Net Income Per Share	'
	Basic and Diluted Net Income (Loss) Per Share
	Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed using the weighted average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued. Potentially dilutive securities include outstanding stock options, including performance-based stock options for which performance criteria have been achieved, restricted stock units and shares to be purchased under the employee stock purchase plan. The dilutive effect of potentially dilutive securities is reflected in diluted earnings per common share by application of the treasury stock method. Under the treasury stock method, an increase in the fair market value of the Company's common stock can result in a greater dilutive effect from potentially dilutive securities.
	The computations of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2014		2013
	Numerator:
	Net income (loss)	$	18,275	$	(51,911	)
	Denominator:
	Weighted average common shares - basic	74,754		70,933
	Effect of dilutive securities:
	Employee stock options	3,306		—
	Employee stock purchase plan	4		—
	Restricted stock units	—		—
	Weighted average common shares - diluted	78,064		70,933
	Net income (loss) per share:
	Basic	$	0.24	$	(0.73	)
	Diluted	$	0.23	$	(0.73	)
	Potentially dilutive securities excluded from net income (loss) per share - diluted because their effect is anti-dilutive	658		5,340

StockBased_Compensation_and_St

Stock-Based Compensation and Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Share-Based Compensation and Stockholders' Equity	'
	Stock-Based Compensation and Stockholders’ Equity
	Common Stock
	In March 2013, the Company sold 2,200,000 shares of its common stock in an underwritten public offering at $94.20 per share for net proceeds of $201,023,000 after deducting expenses of the offering. The closing of the offering took place on March 13, 2013.
	Stock Plans
	Pursuant to its 2004 Equity Incentive Award Plan, the Company grants time-based and performance-based stock options, restricted stock units and performance-based restricted stock units.
	Stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Cost of goods sold	$	417		$	—
	Research and development	5,535			11,180
	Selling, general and administrative	7,034			12,398
	Total stock-based compensation	$	12,986		$	23,578
	The following table summarizes the Company's stock option activity for the three months ended March 31, 2014 (in thousands, except per share amounts):
		Number		Weighted
		of		Average
		Shares		Exercise
				Price per Share
	Balance at December 31, 2013	5,111		$	23.54
	Exercised	(858	)	6.03
	Granted	580		74.03
	Forfeited	(54	)	51.01
	Balance at March 31, 2014	4,779		$	33.1
	The following table summarizes all of the Company's restricted stock unit activity for the three months ended March 31, 2014 (in thousands, except per share amounts):
		Shares		Weighted Average Grant Date Fair Value
	Balance at December 31, 2013	—		$	—
	Granted	39		141.46
	Balance at March 31, 2014	39		$	141.46
	The accounting grant date for employee stock options and restricted stock units with performance obligations is the date on which the performance goals have been defined and a mutual understanding of the terms has been reached. The Company's time-based stock option awards and restricted stock units typically vest over a four-year period subject to the employee’s continued service. The Company's performance-based stock options and performance-based restricted stock units granted to executive officers typically vest over a four-year period and five-year period, respectively, subject to the satisfaction of performance criteria established annually for such executive as determined by the Compensation Committee after reviewing the performance reports. The tables above do not include 554,000 performance stock options and 50,000 performance based restricted stock units granted in current and prior fiscal years for which the performance criteria had not been established as of March 31, 2014.
	At March 31, 2014, 2,618,294 shares were available for grant under the Company's 2004 Equity Incentive Award Plan.
	There were no sales under the Employee Stock Purchase Plan ("Purchase Plan") during the three months ended March 31, 2014 and three months ended March 31, 2013. Shares available for future purchase under the Purchase Plan were 526,922 at March 31, 2014.
	Additional paid-in capital increased by $18,473,000 during the three months ended March 31, 2014 as a result of stock-based compensation expense of $13,297,000 and the issuance of common stock upon exercise of stock options of $5,176,000.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	During the fiscal first quarter of 2013, the FASB issued amended guidance clarifying the release of accumulated Foreign Currency Translation from Accumulated Other Comprehensive Income ("AOCI") into current year Net Earnings. The amendment requires that when the parent company ceases to have a controlling interest in a subsidiary or a business within a foreign entity the parent is to release accumulated Foreign Currency Translation from AOCI. This update is required to be adopted for all annual periods and interim reporting periods beginning after December 15, 2013, with early adoption permitted. The adoption of this standard did not have a material impact on the Company's results of operations, cash flows or financial position.
	In July 2013, FASB issued ASU 2013-11, "Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force)." The amendments in this ASU provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The adoption of ASU 2013-11 did not have a material impact on the Company's results of operations, cash flows or financial position.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	Supplemental New Drug Application Filing
	On April 8, 2014, the Company announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA), based on data from the randomized, multi-center, open-label Phase III RESONATETM study, PCYC-1112, a head-to-head comparison of single agent IMBRUVICATM (ibrutinib) versus ofatumumab in 391 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who had received at least one prior therapy. IMBRUVICATM is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
	Acquisition of Technology
	On April 15, 2014, the Company entered into an agreement with a third party to acquire technology assets in the amount of $9,250,000 in cash.

The_Company_and_Significant_Ac1

The Company and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying condensed consolidated financial statements include the accounts of Pharmacyclics, Inc. and its wholly-owned subsidiaries, Pharmacyclics (Europe) Limited, Pharmacyclics Switzerland GmbH, Pharmacyclics Cayman Ltd. and Pharmacyclics (Shanghai) Management Consulting Service Limited. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's consolidated operations.
	The interim condensed consolidated financial statements have been prepared by the Company, without audit, in accordance with Article 10 of Regulation S-X which governs quarterly reporting and, therefore, do not necessarily include all information and footnotes necessary for a fair statement of the Company's financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States ("GAAP"). The December 31, 2013 condensed consolidated balance sheet data contained within this Form 10-Q was derived from audited consolidated financial statements included in the Company's Form 10-K for the year ended December 31, 2013, but does not include all disclosures required by accounting principles generally accepted in the United States.
	In the opinion of management, the unaudited financial information for the interim periods presented reflects all normal and recurring adjustments necessary for a fair statement of results of operations, financial position and cash flows. These condensed consolidated financial statements should be read in conjunction with the financial statements included in the Company's Form 10-K for the year ended December 31, 2013. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year.
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts and the disclosure of contingent amounts in the Company's condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.
Revenue recognition	'
	Revenue recognition
	Product revenue, net is recognized in accordance with the FASB Accounting Standards Codification (ASC) 605, Revenue Recognition, when the following criteria have been met: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured. Revenues are deferred for fees received before earned or until no further obligations exist. The Company exercises judgment in determining that collectability is reasonably assured or that services have been delivered in accordance with the arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the sales price is subject to refund or adjustment. The Company assesses collectability based primarily on the customer's payment history and on the creditworthiness of the customer.
	Product Revenue, Net
	Product revenue, net consists of U.S. sales of IMBRUVICATM and is recognized once all four revenue recognition criteria described above have been met. The Company sells IMBRUVICATM to specialty pharmacies ("SP") that sells to individual patients, specialty distributors ("SD") that sells to hospital pharmacies, and to direct customers. The Company recognizes revenue from sales of IMBRUVICATM when the product’s title and risk of loss transfers to the customer. The Company determined that it has the ability to make reasonable estimates of product returns in order to recognize revenue at the time that title and risk of loss transfers to the customer based on the following factors: (1) the Company believes that it has sufficient insight into the distribution channel at the SP's and SD's in order to ascertain their inventory level and dispense data, (2) due to the price of the Company's product and limited patient population, its SP and SD customers have not built up significant levels of inventory, nor does the Company expect they will do so for the foreseeable future, (3) inventory on hand at the Company's SP customers was generally less than two weeks as of March 31, 2014, (4) there have been no product returns to-date since the Company's commercial launch of IMBRUVICATM on November 13, 2013 and (5) the Company believes there is limited risk of return of inventory in the channel due to expiration based on the shelf life of inventory in the channel.
	The Company recognizes product revenue net of adjustments for customer credits, including estimated government rebates and charge-backs, returns, prompt payment discounts, patient assistance programs, and Medicare Part D coverage gap reimbursements. Each of the above adjustments are recorded at the time of revenue recognition, resulting in a reduction in product revenue, net and an increase in accrued expenses or a reduction in accounts receivable, net. The above adjustments require significant estimates, judgment and information obtained from external sources. If management's estimates differ from actuals, the Company will record adjustments that would affect product revenue, net in the period of adjustment.
	Gross-to-net sales adjustments
	Rebates
	The Company records an allowance for rebates including mandated discounts under the Medicaid Drug Rebate Program. The allowance for rebates is based upon contractual agreements or legal requirements with public sector benefit providers, including Medicaid. The allowance for rebates represents the estimated amounts owed to such public sector benefit providers, including Medicaid, based on the estimated rebate percentage of forecasted eligible Medicaid sales. The estimated rebate percentage is based on statutory discount rates and expected utilization. The forecasted eligible Medicaid sales represents those sales made by the Company that will ultimately be consumed by patients covered by Medicaid. To estimate the allowance for rebates, the Company uses the estimated patient mix information which is provided by our specialty pharmacy customers, as well as third party sources. Rebates are generally invoiced and paid in arrears. As such, the allowance for rebates consists of an estimate of the amount expected to be incurred for the current quarter's shipments to patients, plus an accrual balance for estimated unpaid rebates from prior periods. The allowance for rebates is recorded within Accrued liabilities in the condensed consolidated balance sheets.
	Charge-backs
	Charge-backs are discounts that result from the difference between the prices at which the Company sells IMBRUVICATM to direct customers and the sales price ultimately paid to wholesalers under fixed price contracts by third-party payers. Such third-party payers, which primarily consist of the U.S. Department of Defense, U.S. Department of Veteran's Affairs (VA), Public Health Services (PHS), and other Federal Government institutions purchasing via the Federal Supply Schedule, purchase products through wholesalers at a lower price provided for in fixed price contracts and the wholesalers then charge the Company the difference between their acquisition cost and the lower program price. Charge-backs are recorded as a reduction to accounts receivable, net in the condensed consolidated balance sheets.
	Product Returns
	Consistent with industry practice, the Company generally offers its customers a limited right to return. The Company generally allows for the return of product that is a few months prior to and up to a few months after the product expiration date. Additionally, the Company considers several other factors in the estimation process including the expiration dates of product shipped, third party data in monitoring channel inventory levels, shelf life of the product, prescription trends and other relevant factors. Provisions for estimated product returns are recorded within Accrued liabilities in the condensed consolidated balance sheets.
	Medicare Part D coverage gap
	Medicare Part D, also known as the Medicare prescription drug benefit, is a federal program to subsidize the costs of prescription drugs for Medicare beneficiaries in the United States. The Medicare Part D prescription drug benefit mandates that drug manufacturers fund 50% of the Medicare Part D insurance coverage gap for prescription drugs sold to eligible patients. Funding of the Medicare Part D gap is invoiced and paid in arrears. As such, the allowance for Medicare Part D consists of an estimate of the amount expected to be incurred for the current quarter's shipments to patients, plus an accrual balance for estimated shipments remaining in the channel at period end which are estimated to ship to Medicare Part D patients. The allowance for rebates is recorded within Accrued liabilities in the condensed consolidated balance sheets.
	Prompt payment discounts
	The Company generally offers cash discounts to its customers, generally a 2% discount applied to the invoice amount, as an incentive for prompt payment. The Company expects that all of its customers to whom it offers cash discounts for prompt payment to take advantage of the full amount of the 2% discount. The Company records the prompt-payment discount as a reduction to Accounts receivable, net in the condensed consolidated balance sheets.
	Co-payment assistance
	Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment assistance. The Company accrues for co-payment assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators.
Concentration of credit risk	'
	Concentration of credit risk
	Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, marketable securities, accounts receivable and receivables from collaboration partners. The Company places its cash and cash equivalents with high-credit quality financial institutions and invests in debt instruments of financial institutions, corporations and government entities with strong credit ratings. The Company's management believes it has established guidelines relative to credit quality, diversification and maturities that maintain safety and liquidity.

Product_Revenue_Net_Tables

Product Revenue, Net (Tables)	3 Months Ended
	Mar. 31, 2014
Revenues [Abstract]	'
Schedule of Provisions, Credits and Payments	'
	The following table summarizes the provisions, and credits/payments, for product revenue, net adjustments (in thousands):
			Total
	Balance as of December 31, 2013		$	1,206
	Provision related to current period sales		8,639
	Credits/payments		(2,095		)
	Balance as of March 31, 2014		$	7,750
Schedule of Customers Who Represent 10% or More of the Company's Revenue	'
	The following table sets forth customers who represented 10% or more of the Company's product revenue, net for the three months ended March 31, 2014:
		Three Months Ended
	Customer	31-Mar-14
	A	29	%
	B	19	%
	C	13	%
	D	12	%

Collaboration_and_Other_Agreem1

Collaboration and Other Agreements (Tables)	3 Months Ended
	Mar. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Schedule of Revenue Related to Collaboration and License Arrangements	'
	The Company recognized revenue related to its collaboration and license arrangements as follows (in thousands):
		Three Months Ended March 31,
		2014			2013
	Janssen	$	63,135		$	2,786
	Les Laboratoires Servier ("Servier")	63			40
	Other	—			20
	Total	$	63,198		$	2,846
Janssen [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Schedule of Revenue Related to Collaboration and License Arrangements	'
	Total revenue recognized with respect to the Agreement consisted of the following (in thousands):
		Three Months Ended March 31,
		2014			2013
	License and milestone revenue	$	60,000		$	—
	Collaboration services revenue	3,135			2,786
	Total	$	63,135		$	2,786
Schedule of Collaborative Arrangements,Recognized Costs	'
	During the three months ended March 31, 2014 and the three months ended March 31, 2013, the Company's share of costs under the Agreement was calculated as follows:
		Three Months Ended
		March 31,
		2014			2013
	Research and development	$	24,402		$	22,172
	Selling, general and administrative	18,165			2,697
		42,567			24,869
	Less: Pharmacyclics' 50% share of net product revenue less cost of goods sold	25,035			—
	Total net costs for IMBRUVICATM under the Agreement (1)	$	17,532		$	24,869
	(1) The Company's total share of net costs under the Agreement did not exceed the $50,000,000 annual cap provided for in the Agreement. As such, no Excess Amounts were recorded for the three months ended March 31, 2014 and March 31, 2013.
	Expenses which were charged to the collaboration are as follows (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Collaboration expenses, unadjusted	$	32,365		$	38,463
	Decrease for cost sharing	(7,963		)	(16,291		)
	Research and development	$	24,402		$	22,172
	Collaboration expenses, unadjusted	$	18,220		$	3,508
	Decrease for cost sharing	(55		)	(811		)
	Selling, general and administrative	$	18,165		$	2,697
Schedule of Collaborative Arrangements, Share of Product Revenue, Net	'
	For the three months ended March 31, 2014, Janssen's 50% share from net product revenue less cost of goods sold of IMBRUVICATM of $25,035,000 was included in Costs of collaboration in the Company's condensed consolidated statements of operations. Janssen's share was calculated as follows:
		Three Months Ended
		31-Mar-14
	Product revenue, net	$	56,179
	Less: Cost of goods sold	6,110
		50,069
	Janssen's share of pre-tax profits	50		%
	Total Cost of Collaboration (Janssen's 50% share as per the Agreement)	$	25,035
	Pharmacyclics' 50% share of net product revenue less cost of goods sold	$	25,035
Servier [Member}	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Schedule of Revenue Related to Collaboration and License Arrangements	'
	Total revenue recognized with respect to the Company's collaboration and license agreement with Servier consisted of the following (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Collaboration services revenue	$	63		$	40
	Total	$	63		$	40

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	The components of inventory are as follows (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	14,899	$	8,007
	Work-in-process	11,651		3,489
	Finished goods	2,164		1,107
		$	28,714	$	12,603

Fair_Value_Measurements_and_Ma1

Fair Value Measurements and Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2014
Assets, Fair Value Disclosure [Abstract]	'
Available-For-Sale Securities Reconciliation	'
	The following is a summary of the Company's available-for-sale securities at March 31, 2014 and December 31, 2013, respectively (in thousands):
	As of March 31, 2014		Amortized Cost			Unrealized Gain			Unrealized Loss				Estimated Fair Value
	U.S. agency securities – FDIC insured		$	11,440		$	—		$	(9	)		$	11,431
	Total marketable securities		$	11,440		$	—		$	(9	)		$	11,431
	As of December 31, 2013		Amortized Cost			Unrealized Gain			Unrealized Loss				Estimated Fair Value
	U.S. agency securities – FDIC insured		$	11,680		$	—		$	(8	)		$	11,672
	Total marketable securities		$	11,680		$	—		$	(8	)		$	11,672
Remaining Contractual Maturities on Marketable Securities	'
	At March 31, 2014, the Company's marketable securities had the following remaining contractual maturities (in thousands):
		Amortized Cost			Estimated Fair Value
	Less than one year	$	11,440		$	11,431
Basis of Fair Value Measurements for Available-For-Sale Securities	'
	The following table sets forth the basis of fair value measurements for the Company's cash equivalents and available-for-sale securities as of March 31, 2014 and December 31, 2013 (in thousands):
		March 31, 2014
		Level 1			Level 2			Level 3				Fair value
	Cash equivalents:
	U.S. treasury bills	$	474,985		$	—		$	—			$	474,985
	Money market funds	79,304			—			—				79,304
	U.S. agency securities - FDIC insured	—			240			—				240
	Marketable securities:
	U.S. agency securities - FDIC insured	—			11,431			—				11,431
		$	554,289		$	11,671		$	—			$	565,960
		31-Dec-13
		Level 1			Level 2			Level 3				Fair value
	Cash equivalents:
	U.S. treasury bills	$	269,488		$	—		$	—			$	269,488
	Money market funds	129,193			—			—				129,193
	U.S. agency securities - FDIC insured	—			240			—				240
	Marketable securities:
	U.S. agency securities - FDIC insured	—			11,672			—				11,672
		$	398,681		$	11,912		$	—			$	410,593

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2014
Balance Sheet Related Disclosures [Abstract]	'
Schedule of Property Plant and Equipment	'
	Property and equipment, net, consists of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Equipment	$	12,559		$	11,827
	Leasehold improvements	5,528			5,493
	Furniture and fixtures	1,278			1,278
	Construction in progress	19,065			14,592
		38,430			33,190
	Less: Accumulated depreciation and amortization	(8,630		)	(7,719		)
		$	29,800		$	25,471
Schedule of Accrued Liabilities	'
	Accrued liabilities consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Accrued clinical related	$	17,166		$	17,062
	Accrued payroll and employee related expenses	16,006			20,500
	Accrued inventory	1,528			7,592
	Gross to net accruals	5,995			905
	Accrued contract manufacturing	1,256			1,556
	Accrued royalty	4,167			949
	Accrued outside services	3,583			5,077
	Accrued property and equipment purchases	3,028			4,039
	Accrued value added taxes	1,654			7,041
	Accrued other	8,778			6,467
		$	63,161		$	71,188
Deferred Revenue	'
	Deferred revenue consists of the following (in thousands):
	Current portion:	March 31,			December 31,
		2014			2013
	Deferred revenue related to Janssen	$	12,297		$	7,505
	Deferred revenue related to net product sales	565			76
		$	12,862		$	7,581
	Non-current portion:	March 31,			December 31,
		2014			2013
	Deferred revenue from Janssen	$	44,648		$	52,025

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Future Minimum Lease Payments	'
	As of March 31, 2014, the Company's future minimum lease payments under non-cancelable operating leases are as follows:
	Fiscal year	Operating Lease Commitments
	2014 (remaining nine months)	$	1,677
	2015	2,092
	2016	2,161
	2017	2,112
	2018	857
	2019	882
	Thereafter	2,890
	Total	$	12,671

Basic_and_Diluted_Net_Income_P1

Basic and Diluted Net Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Computation of Basic and Diluted Net Income Per Share	'
	The computations of basic and diluted net income (loss) per share are as follows (in thousands, except per share amounts):
		Three Months Ended
		March 31,
		2014		2013
	Numerator:
	Net income (loss)	$	18,275	$	(51,911	)
	Denominator:
	Weighted average common shares - basic	74,754		70,933
	Effect of dilutive securities:
	Employee stock options	3,306		—
	Employee stock purchase plan	4		—
	Restricted stock units	—		—
	Weighted average common shares - diluted	78,064		70,933
	Net income (loss) per share:
	Basic	$	0.24	$	(0.73	)
	Diluted	$	0.23	$	(0.73	)
	Potentially dilutive securities excluded from net income (loss) per share - diluted because their effect is anti-dilutive	658		5,340

StockBased_Compensation_and_St1

Stock-Based Compensation and Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Share-based Compensation Recognized in Statements of Operations	'
	Stock-based compensation expense recognized in the condensed consolidated statements of operations was as follows (in thousands):
		Three Months Ended
		March 31,
		2014			2013
	Cost of goods sold	$	417		$	—
	Research and development	5,535			11,180
	Selling, general and administrative	7,034			12,398
	Total stock-based compensation	$	12,986		$	23,578
Stock Option Activity	'
	The following table summarizes the Company's stock option activity for the three months ended March 31, 2014 (in thousands, except per share amounts):
		Number		Weighted
		of		Average
		Shares		Exercise
				Price per Share
	Balance at December 31, 2013	5,111		$	23.54
	Exercised	(858	)	6.03
	Granted	580		74.03
	Forfeited	(54	)	51.01
	Balance at March 31, 2014	4,779		$	33.1
Restricted Stock Units Activity	'
	The following table summarizes all of the Company's restricted stock unit activity for the three months ended March 31, 2014 (in thousands, except per share amounts):
		Shares		Weighted Average Grant Date Fair Value
	Balance at December 31, 2013	—		$	—
	Granted	39		141.46
	Balance at March 31, 2014	39		$	141.46

The_Company_and_Significant_Ac2

The Company and Significant Accounting Policies (Details)	3 Months Ended		3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
		Accounts Receivable [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]	Customer Concentration Risk [Member]
		Customer	Customer One [Member]	Customer Two [Member]	Customer Three [Member]	Customer Four [Member]	Customer Five [Member]
			Accounts Receivable [Member]	Accounts Receivable [Member]	Accounts Receivable [Member]	Accounts Receivable [Member]	Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'	'	'	'	'
Trade discount for early payment	2.00%	'	'	'	'	'	'
Number of customers that counted for more than 10% of accounts receivable	'	5	'	'	'	'	'
Customer percentage of accounts receivable	'	'	30.00%	16.00%	15.00%	11.00%	10.00%

Product_Revenue_Net_Summary_of

Product Revenue, Net - Summary of Provisions and Credit Payments (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Activity of Sales Related Deductions [Roll Forward]	'
Beginning Balance	$1,206
Provision related to current period sales	8,639
Credits/payments	-2,095
Ending Balance	$7,750

Product_Revenue_Net_Product_Re

Product Revenue, Net Product Revenue by Customer (Details) (Sales Revenue, Product Line [Member], Customer Concentration Risk [Member])	3 Months Ended
	Mar. 31, 2014
Customer A	'
Concentration Risk [Line Items]	'
Customer percentage of product revenue	29.00%
Customer B	'
Concentration Risk [Line Items]	'
Customer percentage of product revenue	19.00%
Customer C	'
Concentration Risk [Line Items]	'
Customer percentage of product revenue	13.00%
Customer D	'
Concentration Risk [Line Items]	'
Customer percentage of product revenue	12.00%

Collaboration_and_License_Agre

Collaboration and License Agreements Recognized Revenue (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
License and milestone revenue	$60,000	$0
Collaboration services revenue	3,198	2,846
Total revenue	119,377	2,846
Collaborative Arrangement [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Total revenue	63,198	2,846
Janssen [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
License and milestone revenue	63,135	2,786
Servier [Member}	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
License and milestone revenue	63	40
Other Entities [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
License and milestone revenue	0	20
Collaboration and License Agreement with Les Laboratories Servier [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Collaboration services revenue	63	40
Total revenue	63	40
Collaboration and License Agreement with Janssen Biotech Inc [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
License and milestone revenue	60,000	0
Collaboration services revenue	3,135	2,786
Total revenue	$63,135	$2,786

Collaboration_and_License_Agre1

Collaboration and License Agreement with Janssen Biotech, Inc - Narrative (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Dec. 31, 2011

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2011

Mar. 31, 2014

Dec. 31, 2011

Dec. 31, 2011

Mar. 31, 2014

Mar. 31, 2014

Janssen [Member]

Janssen [Member]

Janssen [Member]

Janssen [Member]

Licenses [Member]

Committee Services [Member]

Committee Services [Member]

Development Services [Member]

Development Services [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

IMBRUVICA [Member]

Cost of Collaboration [Member]

Janssen [Member]

Janssen [Member]

Continued Development Progress [Member]

Achievement of Regulatory Progress [Member]

Achievement of Regulatory Progress [Member]

Regulatory Approval [Member]

Collaboration and License Agreement with Janssen Biotech Inc [Member]

IMBRUVICA [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-Refundable Upfront Payment Upon Execution

'

'

'

'

'

'

'

'

$70,605,000

$14,982,000

'

$64,413,000

'

$150,000,000

'

'

'

'

'

'

'

'

'

'

Maximum milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

'

825,000,000

825,000,000

'

'

'

250,000,000

380,000,000

225,000,000

350,000,000

'

'

Cumulative milestone payments triggered under collaboration

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

445,000,000

'

'

'

'

Percent of cost sharing arrangement Janssen share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60.00%

'

'

'

'

'

'

'

'

'

Percent of cost sharing arrangement by company

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40.00%

'

'

'

'

'

'

'

'

'

Sharing percentage pre-tax profit

'

'

50.00%

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

Collaboration Costs

25,035,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,035,000

'

'

'

'

'

'

'

Company's annual cap of development costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000,000

'

'

'

'

'

'

'

'

'

Maximum total excess amounts plus interest

'

'

225,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Incremental interest rate on outstanding balance

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum percentage of interest on outstanding excess amount (in percent)

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum interest on excess amount

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated weighted average cost of capital (in percent)

'

'

12.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum license royalty rates (in percent)

'

'

30.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum license royalty rates (in percent)

'

'

40.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Services revenue recognized period

'

'

'

'

'

'

'

'

'

'

'17 years

'

'9 years

'

'

'

'

'

'

'

'

'

'

'

Milestone payment triggered

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000,000

'

Deferred revenue total under cost sharing agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

56,946,000

'

'

'

'

'

'

'

'

Deferred revenue - non-current portion

44,648,000

'

'

52,025,000

44,648,000

52,025,000

'

'

'

'

'

'

'

'

'

44,648,000

'

'

'

'

'

'

'

'

Cost of goods sold

6,110,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,035,000

Receivables from Collaboration Partners, Current

1,047,000

'

'

51,957,000

1,047,000

50,230,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value Added Tax Receivable, Current

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,607,000

'

'

'

'

'

'

Accounts Payable

'

'

'

'

17,890,000

3,142,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value added taxes

'

'

'

'

246,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total excess amounts funded by Janssen

'

'

'

'

'

'

135,634,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Excess Amounts Funded by Janssen

'

'

'

'

'

'

134,261,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest on outstanding excess amount

'

'

'

'

'

'

$1,373,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration_and_License_Agre2

Collaboration and License Agreement with Janssen Biotech, Inc - Collaboration Costs (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Research and development	$35,292	$35,784
Selling, general and administrative	34,715	20,026
Collaboration and License Agreement with Janssen Biotech Inc [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Research and development	24,402	22,172
Selling, general and administrative	18,165	2,697
Collaboration Expense, Unadjusted [Member] | Collaboration and License Agreement with Janssen Biotech Inc [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Research and development	32,365	38,463
Selling, general and administrative	18,220	3,508
Increase (Decrease) for Cost Sharing [Member] | Collaboration and License Agreement with Janssen Biotech Inc [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Research and development	-7,963	-16,291
Selling, general and administrative	($55)	($811)

Collaboration_and_Other_Agreem2

Collaboration and Other Agreements Collaboration and License Agreement with Janssen Biotech, Inc. - Share of Cost (Details) (USD $)	3 Months Ended				12 Months Ended
	Mar. 31, 2014		Mar. 31, 2013		Dec. 31, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'		'
Research and development	$35,292,000		$35,784,000		'
Selling, general and administrative	34,715,000		20,026,000		'
Subtotal	101,152,000		55,810,000		'
Collaboration and License Agreement with Janssen Biotech Inc [Member]	'		'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'		'
Research and development	24,402,000		22,172,000		'
Selling, general and administrative	18,165,000		2,697,000		'
Subtotal	42,567,000		24,869,000		'
Less: Pharmacyclics' 50% share of net product revenue less cost of goods sold	25,035,000		0		'
Total net costs for IMBRUVICA under the Agreement	17,532,000	[1]	24,869,000	[1]	'
Company's annual cap of development costs	'		'		$50,000,000
[1]	The Company's total share of net costs under the Agreement did not exceed the $50,000,000 annual cap provided for in the Agreement. As such, no Excess Amounts were recorded for the three months ended March 31, 2014 and March 31, 2013.

Collaboration_and_Other_Agreem3

Collaboration and Other Agreements Collaborative and License Agreement with Janssen Biotech, Inc. - Share of Revenues, Net (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Product revenue, net	$56,179,000	$0	'
Cost of goods sold	6,110,000	0	'
Net Product Revenue Less Cost of Goods Sold	50,069,000	'	'
Janssen's share of pre-tax profits	'	'	50.00%
Total Cost of Collaboration (Janssen's 50% share as per the Agreement)	25,035,000	0	'
Janssen [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Janssen's share of pre-tax profits	'	'	50.00%
Collaboration and License Agreement with Janssen Biotech Inc [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Pharmacyclics' 50% share of net product revenue less cost of goods sold	25,035,000	0	'
Collaboration and License Agreement with Janssen Biotech Inc [Member] | Janssen [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Janssen's share of pre-tax profits	50.00%	'	'
Total Cost of Collaboration (Janssen's 50% share as per the Agreement)	$25,035,000	'	'

Collaboration_and_License_Agre3

Collaboration and License Agreement with Les Laboratories Servier - Narrative (Details) (Servier [Member}, USD $)	1 Months Ended
	31-May-09	Apr. 30, 2011
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Non-Refundable Upfront Payment Upon Execution	$11,000,000	'
Upfront payment received, net of withholding taxes	10,450,000	'
Additional payments received under collaborative arrangement	4,000,000	'
Research collaboration payment period	'24 months	'
Revenue recognized over, periods	'2 years	'
Maximum milestone payments	24,500,000	'
Milestone payment paid In advance upon achievement of pre-specified events	'	7,000,000
License Agreement Terms [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Maximum milestone payments	10,500,000	'
Achievement of Regulatory Progress [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Maximum milestone payments	5,000,000	'
Regulatory Approval [Member]	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'
Maximum milestone payments	$9,000,000	'

Collaborative_and_License_Agre

Collaborative and License Agreements with Novo Nordisk A/S - Narrative (Details) (Collaboration and License Agreement with Novo Nordisk [Member], USD $)	1 Months Ended
	Oct. 31, 2012
Collaboration and License Agreement with Novo Nordisk [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Non-Refundable Upfront Payment Upon Execution	$5,000,000
Maximum milestone payments	$55,000,000

Collaboration_and_License_Agre4

Collaboration and License Agreement with Celera Corporation - Narrative (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Milestone payment for HDAC Inhibitor	'two-thirds
Milestone payment for Factor VIIa	'one-third
Celera Corporation Agreement [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Maximum milestone payments	97,000,000
Potential future milestone payments to be paid to Celera after regulatory approval	90.00%
Collaborative agreement, termination terms, days written notice to terminate agreement	'60 days
Collaborative agreement, termination terms, days of written notice that breaching party has to cure a breach in contract before termination	'90 days
IMBRUVICA [Member] | Celera Corporation Agreement [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Royalty Expense	3,931,000
HDAC Inhibitor Program [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Percentage of milestone payment that relates to project	66.67%
Factor VIIa Inhibitor Program [Member]	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'
Percentage of milestone payment that relates to project	33.33%

Inventory_Details

Inventory (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$14,899	$8,007
Work-in-process	11,651	3,489
Finished goods	2,164	1,107
Inventory	$28,714	$12,603

AvailableForSale_Securities_Re

Available-For-Sale Securities Reconciliation (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities	'	'
Amortized Cost	$11,440	$11,680
Unrealized Gain	0	0
Unrealized Loss	-9	-8
Estimated Fair Value	11,431	11,672
U.S. agency securities – FDIC insured [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Amortized Cost	11,440	11,680
Unrealized Gain	0	0
Unrealized Loss	-9	-8
Estimated Fair Value	$11,431	$11,672

Contractual_Maturities_of_Mark

Contractual Maturities of Marketable Securities (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Assets, Fair Value Disclosure [Abstract]	'
Less than one year - Amortized Cost	$11,440
Less than one year - Fair Value	$11,431

Fair_Value_Measurements_for_Av

Fair Value Measurements for Available-for-sale Securities (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities	'	'
Marketable Securities, Fair Value Disclosure	$11,431	$11,672
Level 1 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Assets, Fair Value Disclosure	554,289	398,681
Level 2 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Assets, Fair Value Disclosure	11,671	11,912
Level 3 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Assets, Fair Value Disclosure	0	0
Estimated Fair Value [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Assets, Fair Value Disclosure	565,960	410,593
US Treasury Bill Securities [Member] | Level 1 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	474,985	269,488
US Treasury Bill Securities [Member] | Level 2 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
US Treasury Bill Securities [Member] | Level 3 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
US Treasury Bill Securities [Member] | Estimated Fair Value [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	474,985	269,488
Money market funds [Member] | Level 1 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	79,304	129,193
Money market funds [Member] | Level 2 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Money market funds [Member] | Level 3 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Money market funds [Member] | Estimated Fair Value [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	79,304	129,193
U.S. agency securities - FDIC insured [Member] | Level 1 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Marketable Securities, Fair Value Disclosure	0	0
U.S. agency securities - FDIC insured [Member] | Level 2 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	240	240
Marketable Securities, Fair Value Disclosure	11,431	11,672
U.S. agency securities - FDIC insured [Member] | Level 3 [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Marketable Securities, Fair Value Disclosure	0	0
U.S. agency securities - FDIC insured [Member] | Estimated Fair Value [Member]	'	'
Schedule of Available-for-sale Securities	'	'
Cash and Cash Equivalents, Fair Value Disclosure	240	240
Marketable Securities, Fair Value Disclosure	$11,431	$11,672

Balance_Sheet_Components_Prope

Balance Sheet Components - Property, Plant, and Equipment (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment	'	'
Property, plant and equipment, gross	$38,430	$33,190
Less: Accumulated depreciation and amortization	-8,630	-7,719
Property and equipment, net	29,800	25,471
Equipment [Member]	'	'
Property, Plant and Equipment	'	'
Property, plant and equipment, gross	12,559	11,827
Leasehold improvements [Member]	'	'
Property, Plant and Equipment	'	'
Property, plant and equipment, gross	5,528	5,493
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment	'	'
Property, plant and equipment, gross	1,278	1,278
Construction in Progress [Member]	'	'
Property, Plant and Equipment	'	'
Property, plant and equipment, gross	$19,065	$14,592

Balance_Sheet_Components_Accru

Balance Sheet Components - Accrued Liabilities and Payables (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities, Current [Abstract]	'	'
Accrued clinical related	$17,166	$17,062
Accrued payroll and employee related expenses	16,006	20,500
Accrued inventory	1,528	7,592
Gross to net accruals	5,995	905
Accrued contract manufacturing	1,256	1,556
Accrued royalty	4,167	949
Accrued outside services	3,583	5,077
Accrued property and equipment purchases	3,028	4,039
Accrued value added taxes	1,654	7,041
Accrued other	8,778	6,467
Total accrued liabilities	$63,161	$71,188

Balance_Sheet_Components_Defer

Balance Sheet Components - Deferred Revenue (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue - current portion	$12,862	$7,581
Deferred revenue from Janssen	44,648	52,025
Janssen [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue - current portion	12,297	7,505
Deferred revenue from Janssen	44,648	52,025
Sales Revenue, Goods, Net [Member]	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Deferred revenue - current portion	$565	$76

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Income tax benefit	($12)	($974)
Federal statutory income tax rate	35.00%	'

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
	sqft
Commitments and Contingencies [Line Items]	'	'
Leased Space (in square feet)	132,176	'
Facility Total Leased Space in Square Feet	79,776	'
Period for which option to extend lease term is available	'5 years	'
Noncancelable purchase obligation	$12,840	$34,800
Operating Lease Commitments	'	'
2014 (remaining nine months)	1,677	'
2015	2,092	'
2016	2,161	'
2017	2,112	'
2018	857	'
2019	882	'
Thereafter	2,890	'
Total	12,671	'
CALIFORNIA	'	'
Commitments and Contingencies [Line Items]	'	'
Leased Space (in square feet)	7,000	'
Facility Total Leased Space in Square Feet	52,400	'
Additional Leased Space, Square Feet	32,000	'
SWITZERLAND	'	'
Commitments and Contingencies [Line Items]	'	'
Leased Space (in square feet)	7,500	'
Janssen [Member]	'	'
Commitments and Contingencies [Line Items]	'	'
Total excess amounts funded by Janssen	135,634	'
Total Excess Amounts Funded by Janssen	134,261	'
Interest on Outstanding Excess Amount	$1,373	'

Basic_and_Diluted_Net_Income_P2

Basic and Diluted Net Income Per Share (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Numerator:	'	'
Net income (loss)	$18,275	($51,911)
Denominator:	'	'
Weighted average common shares - basic	74,754	70,933
Weighted average common shares - diluted	78,064	70,933
Net income (loss) per share:	'	'
Basic (in dollars per share)	$0.24	($0.73)
Diluted (in dollars per share)	$0.23	($0.73)
Potentially dilutive securities excluded from net income per share - diluted because their effect is anti-dilutive	658	5,340
Employee Stock Option [Member]	'	'
Denominator:	'	'
Effect of Dilutive Securities	3,306	0
Employee Stock Purchase Plan (ESPP) [Member]	'	'
Denominator:	'	'
Effect of Dilutive Securities	4	0
Restricted Stock Units (RSUs) [Member]	'	'
Denominator:	'	'
Effect of Dilutive Securities	0	0

StockBased_Compensation_and_St2

Stock-Based Compensation and Stockholders' Equity Components of stock-based compensation expense (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation	$12,986	$23,578
Cost of Goods Sold [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation	417	0
Research and Development Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation	5,535	11,180
Selling, General and Administrative Expenses [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock-based compensation	$7,034	$12,398

StockBased_Compensation_and_St3

Stock-Based Compensation and Stockholders' Equity Summary of the Company's stock option activity (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Stock Options, Outstanding, Number of Shares Beginning	5,111	'
Stock Options, Exercised, Number of Shares	-858	'
Stock Options, Granted, Number of Shares	580	'
Stock Options, Forfeited, Number of Shares	-54	'
Stock Options, Outstanding, Number of Shares Ending	4,779	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]	'	'
Stock Options, Outstanding, Weighted Average Exercise Price Beginning (in dollars per share)	$33.10	$23.54
Stock Options, Exercised, Weighted Average Exercise Price (in dollars per share)	$6.03	'
Stock Options, Granted, Weighted Average Exercise Price (in dollars per share)	$74.03	'
Stock Options, Forfeited, Weighted Average Exercise Price (in dollars per share)	$51.01	'
Stock Options, Outstanding, Weighted Average Exercise Price Ending (in dollars per share)	$33.10	$23.54

StockBased_Compensation_and_St4

Stock-Based Compensation and Stockholders' Equity Restricted Stock Unit Activity (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014
Number of Shares Underlying Restricted Stock Units (RSUs)	'
Beginning Balance, Shares	0
Granted, Shares	39
Ending Balance, Shares	39
Restricted Stock Units (RSUs)	'
Beginning Balance, Weighted Average Grant Date Fair Value	$0
Granted, Weighted Average Grant Date Fair Value	$141.46
Ending Balance, Weighted Average Grant Date Fair Value	$141.46

StockBased_Compensation_and_St5

Stock-Based Compensation and Stockholders' Equity (Details) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Common stock, shares issued (in shares)	'	2,200,000
Common Stock Issue price (in dollars per share)	'	$94.20
Issuance of common stock, net of issuance costs	$0	$201,023,000
Number of performance options granted with performance goals not set	554,000	'
Number of performance RSUs granted with performance goals not set	50,000	'
Adjustments to additional paid in capital, other	18,473,000	'
Proceeds from exercise of stock options and stock purchase rights	5,180,000	2,261,000
Share-based Compensation	13,297,000	'
Equity Incentive Award Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares available for purchase under the plan	2,618,294	'
PurchasePlan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares available for purchase under the plan	526,922	'
Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Proceeds from exercise of stock options and stock purchase rights	$5,176,000	'

Subsequent_Events_Subsequent_E

Subsequent Events Subsequent Events (Details) (Subsequent Event [Member], USD $)	0 Months Ended
	Apr. 08, 2014	Apr. 15, 2014
	Therapy_Session	Intellectual Property [Member]
	Patient
Subsequent Event [Line Items]	'	'
Number of patients in comparative study	391	'
Number of therapies received by test group patient	1	'
Payments to Acquire Intangible Assets	'	$9,250,000